Abstract:Introduction: Previous study showed the standard dose of immunosuppressants enteric-coated mycophenolate sodium (EC-MPS) might result in unsatisfactory control rate of effective blood concentration and improvable acute rejection rate. This prospective cohort study was designed to evaluate the efficacy and safety of an intensified dosing regimen of EC-MPS in de novo kidney transplant recipients in China. Methods: This prospective cohort study enrolled patients underwent de novo renal transplantation from 2015.6 to 2018.9. Participants were divided into the intensified-dose (week 1: 2160 mg/day; week 2: 1440 mg/day; followed by 720-1080 mg/day) and standard-dose (week 1: 1440 mg/day; week 2: 1080 mg/day; followed by 720-1080 mg/day) groups. Sub-group were analyzed based on mycophenolic acid (MPA)-area under the concentration (AUC): achieved group (defined as patients whose MPA AUC is equal or beyond 40 mg.h/L within Day 7) and under exposure group (defined as patients whose MPA AUC is below 40 mg.h/L within Day 7). The primary endpoints were 12-month-biopsy-proven acute rejection (BPAR), graft and patient survival rates. safety were also assessed. The study was followed up 3 years. Results: A total of 128 patients were included, with 65 and 63 patients in the intensified-dose group and standard-dose group, respectively. The 12-month-BPAR incidence was numerically lower in the intensified-dose group than standard-dose group (4.6% vs. 9.5%, p=0.320). The rate of patients achieving target mycophenolic acid (MPA)-area under the concentration (AUC) was significantly higher in the intensified-dose group (87.5% vs. 69.8%, p=0.015) (Table 1) than standard-dose group, and patients achieving target MPA-AUC had a significantly lower 3-month-BPAR incidence (1.0% vs. 11.1%, p=0.03) (Table 2). patient and graft survival rates at 36 months between the intensified-dose and standard-dose groups was 98.5% vs. 100.0% and 98.5% vs. 100.0%, respectively. The 36-month- de novo donor-specific antibody (dnDSA) positive incidence rates was numerically lower in the intensified-dose group than standard-dose group (1.5% vs. 6.3%, p=0.204). In addition, delayed graft function, treatment failure, serum creatine levels, eGFRs and infection incidence had no significant differences between the two groups (all p>0.05) (Figure 1). The incidence rates of infection were similar in both groups (29.2% vs. 33.3%, p=0.617). No additional safety concerns related to intensified dosing of EC-MPS. Conclusion: Intensified dosing of EC-MPS results in a numerically lower incidence of 12-month-BPAR and lower positive incidence of dnDSA with 36 months follow up. Intensified dosing could help achieve target therapeutic blood concentration of EC-MPS, that showed significantly lower BPAR and no more infection incidence increased and might further improve long-term prognosis in Chinese de novo kidney transplantation recipients.

COUNTRY-DEPENDENT OUTCOME DIFFERENCES AFTER KIDNEY TRANSPLANTATION IN FRANCE VS. GERMANY – AN ADDITIONAL ANALYSIS OF THE ATHENA STUDY

Impact of Everolimus Plus Calcineurin Inhibitor on Formation of Non-Hla Antibodies and Graft Outcomes in Kidney Transplant Recipients: 12-Month Results from the ATHENA Substudy

ATHENA VS HEPHAISTOS - ARE DISCONTINUATION RATES IN MULTICENTER STUDIES DRIVEN BY FACTS OR ATTITUDES?

Effect of Everolimus‐based Drug Regimens on CMV‐specific T‐cell Functionality after Renal Transplantation: 12‐month ATHENA Subcohort‐study Results

Everolimus Plus Reduced Calcineurin Inhibitor Prevents De Novo Anti-Hla Antibodies and Humoral Rejection in Kidney Transplant Recipients: 12-Month Results from the ATHENA Study

CORRELATION OF TROUGH LEVEL COMPLIANCE AND PROTECTION OF RENAL FUNCTION AFTER LIVER TRANSPLANTATION – A POST-HOC ANALYSIS FROM THE HEPHAISTOS STUDY

An Open-Label, Randomized Trial Indicates That Everolimus with Tacrolimus or Cyclosporine is Comparable to Standard Immunosuppression in Denovo Kidney Transplant Patients

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Clinical Analysis of 2520 Renal Transplantations in One Center

Age-related differences in rejection rates, infections and tacrolimus exposure in pediatric kidney transplant recipients - a benchmark study of the CERTAIN registry

Age-related differences in rejection rates, infections and tacrolimus exposure in pediatric kidney transplant recipients in the CERTAIN registry

Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results from the Randomized HEPHAISTOS Trial

A comparison of the epidemiology of kidney replacement therapy between Europe and the United States: 2021 data of the ERA Registry and the USRDS

Positive Long-Term Outcome of Kidney Allocation via Acceptable Mismatch Program in Highly Sensitized Patients

European Survey on Clinical Practice of Detecting and Treating T-Cell Mediated Kidney Transplant Rejection

Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation-A Retrospective Multicenter Outcome Analysis

Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY)

The Outcomes Of Patients With Esrd And Anca-Associated Vasculitis In Australia And New Zealand

Efficacy and Safety of Everolimus with Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplant: Design of a Randomized Study.

Comparison of mid-term clinical outcome in heart transplantation patients using mycophenolate mofetil vs. enteric-coated mycophenolate sodium